Preclinical Evaluation on the Radiohybrid Tandem [18F]La- and [225Ac]Ac-rhPSMA-10.1 for Targeted α-Therapy of Prostate Cancer.
Prostate-specific membrane antigen (PSMA)-targeted α-therapy holds promise for the treatment of prostate cancer but has increased side effects compared with therapy using β-emitting PSMA ligands. This emphasizes the need for precise imaging of the biodistribution of 225Ac-labeled ligands for patient selection and dosim...